306
Participants
Start Date
April 30, 2011
Primary Completion Date
July 31, 2012
Study Completion Date
October 31, 2012
tideglusib
1000 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
tideglusib
1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension
tideglusib
500 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
Placebo
Powder for oral suspension administered once daily in an overnight fasted state for 26 weeks/extension.
Leuven and 4 Additional Cities
Turku and 3 Additional Cities
Paris and 10 Additional Cities
Freiburg and 5 Additional Cities
Madrid and 7 Additional Cities
London and 11 Additional Cities
Lead Sponsor
Collaborators (1)
ICON Clinical Research
INDUSTRY
Noscira SA
INDUSTRY